GleamWall
中文EN

AZTR Azitra, Inc.

Pharmaceutical Preparations · NYSE · SEC CIK 1701478 · Fiscal year ends 12/31

Financial factors as of 2024-12-31 (2024Q4), TTM = sum of the last four quarters

Growth

TTM revenue YoY-98.9%
TTM net income YoY20.5%
TTM EPS YoY71.4%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-146,468.5%
Net margin-119,566.6%
FCF margin-135,885.3%
EBITDA margin-144,793.5%

Returns

ROE-208.3%
ROA-143.8%
ROIC (approx.)-767.7%
Asset turnover0.00x

Leverage & solvency

Liabilities / assets22.6%
Debt / equity0.00x
Current ratio3.80x
Interest coverage-903.38x

Cash quality & payout

Operating cash flow / net income1.14x
Accruals ratio19.5%
Payout ratio—
Capex / revenue114.3%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue———$0$0$0—$0
R&D expense$1.29M$1.35M$1.56M$1.00M$1.18M$1.40M$1.25M$1.12M
SG&A expense$1.61M$2.07M$2.37M$1.22M$1.59M$1.47M$1.85M$1.32M
Operating income-$2.91M-$3.42M-$3.93M-$2.23M-$2.77M-$2.87M-$3.10M-$2.43M
Interest expense$0$1,365$3,411$5,454$372$468$1,293$5,612
Pretax income-$2.95M-$3.35M-$3.93M-$2.23M-$2.76M-$2.89M-$3.07M-$2.38M
Income tax$0$0$0$8,319$0$0$0$9,031
Net income-$2.95M-$3.35M-$3.93M-$2.23M-$2.76M-$2.89M-$3.07M-$2.39M
EBITDA-$2.87M-$3.39M-$3.90M-$2.19M-$2.74M-$2.84M-$3.07M-$2.40M
EPS (basic)-0.29-0.17-0.25—-6.71-1.18-1.55—
EPS (diluted)-0.29-0.17-0.25—-6.71-1.18-1.55—
Weighted avg. shares (diluted)10.30M19.30M15.52M—411,7692.44M1.98M—
Balance sheet
Cash & equivalents$3.75M$6.73M$10.05M$2.07M$1.40M$1.05M$3.21M$4.55M
Receivables$0$909$5,108$912$0$0$0$233
Current assets$4.79M$7.44M$10.76M$3.02M$2.23M$1.80M$3.87M$5.23M
PP&E, net$520,304$536,422$530,438$548,591$579,830$601,504$621,012$653,957
Intangibles$225,789$330,039$334,522$316,673$270,992$258,665$244,140$246,420
Total assets$5.97M$8.92M$12.13M$5.03M$4.30M$3.96M$5.91M$7.36M
Current liabilities$1.54M$1.53M$1.55M$1.07M$1.81M$1.45M$1.28M$1.38M
Total liabilities$1.58M$1.58M$1.65M$1.22M$2.02M$1.73M$1.50M$1.66M
Shareholders' equity$4.40M$7.33M$10.48M$3.80M$2.28M$2.23M$4.41M$5.70M
Shares outstanding6.06M60.60M16.19M1.07M5.60M17.98M14.98M1.15M
Cash flow statement
Operating cash flow-$2.90M-$3.29M-$2.48M-$2.89M-$2.44M-$2.82M-$3.07M-$2.59M
Capital expenditure$18,394$40,053$14,928$9,249$3,363$11,601$0$0
Free cash flow-$2.92M-$3.33M-$2.49M-$2.90M-$2.45M-$2.83M-$3.07M-$2.59M
Investing cash flow-$41,989-$117,541-$37,139-$83,858-$41,078-$36,287-$21,686-$115,532
Financing cash flow-$33,215$85,482$10.50M$3.64M$2.84M$690,343$1.75M-$3,782
Depreciation & amortization$34,513$34,069$37,692$35,010$31,041$31,109$34,055$33,238
Stock-based compensation$12,937$11,405$6,149$12,146$4,165$16,031$30,402$33,178

Free plan shows the latest 8 periods; Pro shows all 19 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.